JP2024502632A5 - - Google Patents

Info

Publication number
JP2024502632A5
JP2024502632A5 JP2023542493A JP2023542493A JP2024502632A5 JP 2024502632 A5 JP2024502632 A5 JP 2024502632A5 JP 2023542493 A JP2023542493 A JP 2023542493A JP 2023542493 A JP2023542493 A JP 2023542493A JP 2024502632 A5 JP2024502632 A5 JP 2024502632A5
Authority
JP
Japan
Prior art keywords
domain
sequence
seq
nucleic acid
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502632A (ja
Filing date
Publication date
Priority claimed from CN202110036169.2A external-priority patent/CN113234682B/zh
Application filed filed Critical
Publication of JP2024502632A publication Critical patent/JP2024502632A/ja
Publication of JP2024502632A5 publication Critical patent/JP2024502632A5/ja
Pending legal-status Critical Current

Links

JP2023542493A 2021-01-12 2021-11-29 Cd7を標的とする改変免疫細胞、キメラ抗原受容体、cd7ブロッキング分子およびその応用 Pending JP2024502632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110036169.2A CN113234682B (zh) 2021-01-12 2021-01-12 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
CN202110036169.2 2021-01-12
PCT/CN2021/133817 WO2022151851A1 (zh) 2021-01-12 2021-11-29 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用

Publications (2)

Publication Number Publication Date
JP2024502632A JP2024502632A (ja) 2024-01-22
JP2024502632A5 true JP2024502632A5 (cg-RX-API-DMAC7.html) 2024-10-02

Family

ID=77130068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542493A Pending JP2024502632A (ja) 2021-01-12 2021-11-29 Cd7を標的とする改変免疫細胞、キメラ抗原受容体、cd7ブロッキング分子およびその応用

Country Status (8)

Country Link
US (1) US20240075143A1 (cg-RX-API-DMAC7.html)
EP (1) EP4279585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502632A (cg-RX-API-DMAC7.html)
KR (1) KR20230134133A (cg-RX-API-DMAC7.html)
CN (3) CN115786271B (cg-RX-API-DMAC7.html)
AU (1) AU2021418636A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204370A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022151851A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786271B (zh) * 2021-01-12 2025-07-22 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
CN114716564B (zh) * 2021-12-20 2023-02-28 四川大学华西医院 基于sectm1构建的嵌合抗原受体免疫细胞制备及其应用
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN114560943B (zh) * 2022-02-28 2022-12-16 先进生物(苏州)有限公司 Cd7-car-t细胞及其制备方法和应用
CN115806618B (zh) * 2022-03-30 2025-11-11 河北森朗生物科技有限公司 一种抗cd7的纳米抗体vhh12及其相关产品、方法和用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116003631B (zh) * 2022-11-15 2024-01-26 江苏元晟生物科技有限公司 靶向cd7的人源化抗体及其应用
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN120865430A (zh) * 2024-04-30 2025-10-31 合源生物科技(天津)有限公司 一种增强型嵌合抗原受体及其应用
CN120866421B (zh) * 2025-09-28 2026-03-03 深圳细胞谷生物医药有限公司 无电转、批量制备免疫细胞治疗产品的方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183041A2 (en) * 1999-05-28 2002-03-06 Immunex CorporatioN Ligand for cd7, and methods for use thereof
US20040202675A1 (en) * 2002-12-09 2004-10-14 Duke University Vaccine adjuvant
HRP20220890T1 (hr) * 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US11390658B2 (en) * 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN118581046A (zh) * 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
CA3067244A1 (en) * 2017-06-12 2018-12-20 Children's Healthcare Of Atlanta, Inc. T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
CA3119296A1 (en) * 2018-11-14 2020-05-22 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof
CN110760007B (zh) * 2019-11-21 2022-08-26 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
CN115786271B (zh) * 2021-01-12 2025-07-22 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用

Similar Documents

Publication Publication Date Title
JP2020517295A5 (cg-RX-API-DMAC7.html)
JP2021094037A5 (cg-RX-API-DMAC7.html)
EP3333183B1 (en) Targeted/immunomodulatory fusion proteins and methods for making same
JP2018535701A5 (cg-RX-API-DMAC7.html)
JP2025028239A5 (cg-RX-API-DMAC7.html)
JP2021087455A5 (cg-RX-API-DMAC7.html)
JP2022501043A5 (cg-RX-API-DMAC7.html)
FI4324851T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
IL277079B1 (en) Cartyrin compositions and methods for use
GB2611448A (en) Polypeptide useful in adoptive cell therapy
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2023059873A5 (cg-RX-API-DMAC7.html)
JP2020533958A5 (cg-RX-API-DMAC7.html)
JP2019527557A5 (cg-RX-API-DMAC7.html)
JP2018525033A5 (cg-RX-API-DMAC7.html)
KR20230011959A (ko) 동종이계 이식을 위한 조작된 면역 세포
FI3710067T3 (fi) Polypeptidejä sisältävä d-domeeni ja niiden käyttötarkoitukset
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2021532742A5 (cg-RX-API-DMAC7.html)
JP2017524367A5 (cg-RX-API-DMAC7.html)
JP2024527557A5 (cg-RX-API-DMAC7.html)
JP2024513906A5 (cg-RX-API-DMAC7.html)
JP2022545815A5 (cg-RX-API-DMAC7.html)
JP2024534847A5 (cg-RX-API-DMAC7.html)
JP2025505546A5 (cg-RX-API-DMAC7.html)